DE69333182D1 - Therapeutische konjugate von toxinen und medikamenten - Google Patents

Therapeutische konjugate von toxinen und medikamenten

Info

Publication number
DE69333182D1
DE69333182D1 DE69333182T DE69333182T DE69333182D1 DE 69333182 D1 DE69333182 D1 DE 69333182D1 DE 69333182 T DE69333182 T DE 69333182T DE 69333182 T DE69333182 T DE 69333182T DE 69333182 D1 DE69333182 D1 DE 69333182D1
Authority
DE
Germany
Prior art keywords
conjugate
cell
toxin
conjugation
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69333182T
Other languages
English (en)
Other versions
DE69333182T2 (de
Inventor
J Hansen
L Griffiths
Anastasia Lentine-Jones
M Goldenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunomedics Inc
Original Assignee
Immunomedics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunomedics Inc filed Critical Immunomedics Inc
Publication of DE69333182D1 publication Critical patent/DE69333182D1/de
Application granted granted Critical
Publication of DE69333182T2 publication Critical patent/DE69333182T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6839—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting material from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1048—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell determinant being a carcino embryonic antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1282—Devices used in vivo and carrying the radioactive therapeutic or diagnostic agent, therapeutic or in vivo diagnostic kits, stents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/534—Production of labelled immunochemicals with radioactive label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
DE69333182T 1992-05-11 1993-05-07 Therapeutische konjugate von toxinen und medikamenten Expired - Lifetime DE69333182T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US07/882,177 US5541297A (en) 1988-04-01 1992-05-11 Therapeutic conjugates of toxins and drugs
US882177 1992-05-11
PCT/US1993/004136 WO1993023062A1 (en) 1992-05-11 1993-05-07 Therapeutic conjugates of toxins and drugs

Publications (2)

Publication Number Publication Date
DE69333182D1 true DE69333182D1 (de) 2003-10-09
DE69333182T2 DE69333182T2 (de) 2004-07-15

Family

ID=25380048

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69333182T Expired - Lifetime DE69333182T2 (de) 1992-05-11 1993-05-07 Therapeutische konjugate von toxinen und medikamenten

Country Status (10)

Country Link
US (2) US5541297A (de)
EP (2) EP0651646B1 (de)
JP (1) JP2942356B2 (de)
AT (1) ATE248858T1 (de)
CA (1) CA2118032C (de)
DE (1) DE69333182T2 (de)
DK (1) DK0651646T3 (de)
ES (1) ES2208639T3 (de)
PT (1) PT651646E (de)
WO (1) WO1993023062A1 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5541297A (en) * 1988-04-01 1996-07-30 Immunomedics, Inc. Therapeutic conjugates of toxins and drugs
EP0622082A4 (de) * 1992-07-28 1996-12-04 Toray Industries Immunkomplex.
US5443953A (en) * 1993-12-08 1995-08-22 Immunomedics, Inc. Preparation and use of immunoconjugates
US6312699B1 (en) * 1994-03-28 2001-11-06 Uab Research Foundation Ligands added to adenovirus fiber
US5690935A (en) * 1995-01-13 1997-11-25 Regents Of The University Of Minnesota Biotherapy of cancer by targeting TP-3/P80
WO1998016254A1 (en) 1996-10-17 1998-04-23 Immunomedics, Inc. Non-antigenic toxin-conjugate and fusion protein of internalizing receptor system
ATE444760T1 (de) * 1997-01-13 2009-10-15 Univ Emory Glutathion zur behandlung von influenzainfektionen
ATE427966T1 (de) 1997-02-11 2009-04-15 Immunomedics Inc Stimulation einer immunantwort durch antikírper, welche mit dem alpha-galaktosylepitop markiert sind
US6251866B1 (en) 1997-08-05 2001-06-26 Watson Laboratories, Inc. Conjugates targeted to the interleukin-2 receptor
CA2299368A1 (en) * 1997-08-05 1999-02-18 Watson Pharmaceuticals, Inc. Conjugates targeted to the interleukin-2 receptor
WO1999008710A1 (en) * 1997-08-15 1999-02-25 Regents Of The University Of Minnesota BIOTHERAPY OF CANCER BY TARGETING TP-3/p80
US7405320B2 (en) 1998-06-22 2008-07-29 Immunomedics, Inc. Therapeutic and diagnostic conjugates for use with multispecific antibodies
AU2007201753B2 (en) * 1998-07-22 2008-11-27 Osprey Pharmaceuticals Usa, Inc. Nucleic acid molecules encoding cytotoxic conjugates that contain a chemokine receptor targeting agent
IL140893A0 (en) * 1998-07-22 2002-02-10 Osprey Pharmaceuticals Ltd Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
US6998106B1 (en) 1998-12-01 2006-02-14 Duke University Radioconjugation of internalizing antibodies
AU2002332637A1 (en) * 2001-08-22 2003-03-10 Watson Pharmaceuticals, Inc. Conjugates targeted to target receptors
US7053188B2 (en) 2002-02-22 2006-05-30 Purdue Research Foundation Monoclonal antibodies specific for neoplasia-specific NADH:disulfide reductase
US7591994B2 (en) 2002-12-13 2009-09-22 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US8877901B2 (en) 2002-12-13 2014-11-04 Immunomedics, Inc. Camptothecin-binding moiety conjugates
DE10209821A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung von Proteinen an ein modifiziertes Polysaccharid
US20060024289A1 (en) * 2002-10-02 2006-02-02 Ruggles Sandra W Cleavage of VEGF and VEGF receptor by wild-type and mutant proteases
US7939304B2 (en) * 2002-10-02 2011-05-10 Catalyst Biosciences, Inc. Mutant MT-SP1 proteases with altered substrate specificity or activity
EP1419786A1 (de) * 2002-11-13 2004-05-19 Bracco Imaging S.p.A. Verfahren zur quantitativen und selektiven Funktionalisierung von Immunoglobulin-Fab-Fragmenten, deren Konjugate und deren Zusammensetzungen
US7651689B2 (en) * 2002-11-15 2010-01-26 Albert Einstein College Of Medicine Of Yeshiva University Methods of applying ionization radiation for therapy of infections
US20040180054A1 (en) * 2003-03-13 2004-09-16 Hanmi Pharm. Co., Ltd. Physiologically active polypeptide conjugate having prolonged in vivo half-life
US20050176108A1 (en) * 2003-03-13 2005-08-11 Young-Min Kim Physiologically active polypeptide conjugate having prolonged in vivo half-life
AU2004223829A1 (en) * 2003-03-24 2004-10-07 Sequoia Pharmaceuticals, Inc. Long acting biologically active conjugates
US20050014932A1 (en) * 2003-05-15 2005-01-20 Iogenetics, Llc Targeted biocides
US7566447B2 (en) 2003-05-15 2009-07-28 Iogenetics, Llc Biocides
US8703134B2 (en) 2003-05-15 2014-04-22 Iogenetics, Llc Targeted cryptosporidium biocides
US8394379B2 (en) * 2003-05-15 2013-03-12 Iogenetics, Llc Targeted cryptosporidium biocides
WO2005014655A2 (en) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
WO2005026325A2 (en) * 2003-09-10 2005-03-24 Surromed, Inc, Bivalent targeting of cell surfaces
US20050148534A1 (en) * 2003-09-22 2005-07-07 Castellino Angelo J. Small molecule compositions and methods for increasing drug efficiency using compositions thereof
EP1733056B1 (de) 2004-03-31 2013-05-22 The General Hospital Corporation Verfahren zur bestimmung des ansprechens eines tumors auf behandlungen mit dem epidermalen wachstumsfaktor-rezeptor als target
EP2308967B1 (de) 2004-04-12 2017-08-23 Catalyst Biosciences, Inc. Mutante mt-sp1 polypeptide
US20050247330A1 (en) * 2004-04-30 2005-11-10 Hp Intellectual Corp. Liquid presence sensor
US20060018827A1 (en) * 2004-07-08 2006-01-26 Ekaterina Dadachova Positron therapy of inflammation, infection and disease
CA2585017A1 (en) * 2004-10-20 2006-12-14 Iogenetics, Llc Biocides
CA2549663A1 (en) * 2005-06-06 2006-12-06 University Of Northern British Columbia Endoribonuclease and uses thereof
EP2674440B1 (de) 2005-12-16 2019-07-03 IBC Pharmaceuticals, Inc. Polyvalente bioaktive anordnungen auf immunglobulinbasis
EP2046951B1 (de) 2006-07-05 2011-10-26 Catalyst Biosciences, Inc. Protease-screening-verfahren und dadurch identifizierte proteasen
JP2008111824A (ja) * 2006-09-01 2008-05-15 Nox Technologies Inc 腫瘍特異的ｔＮＯＸアイソフォーム及び方法
WO2008146854A1 (ja) * 2007-05-28 2008-12-04 National Institute Of Advanced Industrial Science And Technology 抗モータリン抗体のパラトープ及びエピトープ
JP5142265B2 (ja) * 2007-05-28 2013-02-13 独立行政法人産業技術総合研究所 抗モータリン抗体のパラトープ及びエピトープ
JP5189098B2 (ja) 2007-08-23 2013-04-24 三菱化学メディエンス株式会社 非特異反応抑制剤
CN102159247A (zh) * 2008-07-30 2011-08-17 日东电工株式会社 药物载体
HUE062339T2 (hu) 2009-02-13 2023-10-28 Immunomedics Inc Sejten belül hasítható kötést tartalmazó immunkonjugátumok
EP2528938A4 (de) 2010-01-27 2013-10-23 Childrens Medical Center Proangiogene fragmente von prominin-1 und verwendungen davon
WO2013096455A1 (en) 2011-12-20 2013-06-27 Dana-Farber Cancer Institute, Inc. Methods for diagnosing and treating oncogenic kras-associated cancer
EP4306123A3 (de) 2011-12-22 2024-04-17 Children's Medical Center Corporation Aus saposin-a gewonnene peptide und verwendungen davon
CA2874521A1 (en) 2012-05-24 2013-11-28 Dana-Farber Cancer Institute, Inc. Targeting the glutamine to pyruvate pathway for treatment of oncogenic kras-associated cancer
US20150285802A1 (en) 2012-07-18 2015-10-08 Dana-Farber Cancer Institute, Inc. Methods for treating, preventing and predicting risk of developing breast cancer
WO2014092804A1 (en) 2012-12-13 2014-06-19 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
WO2015050844A1 (en) 2013-10-01 2015-04-09 Dana-Farber Cancer Institute, Inc. Methods of treating cancer with atovaquone-related compounds
CN106659764B (zh) 2014-03-26 2021-11-02 儿童医学中心公司 环状鞘脂激活蛋白原肽及其用途
US10350264B2 (en) 2014-03-27 2019-07-16 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating NCOA4-mediated autophagic targeting of ferritin
EP3316885B1 (de) 2015-07-01 2021-06-23 Immunomedics, Inc. Antikörper-sn-38-immunkonjugate mit einem cl2a-linker
WO2017218959A1 (en) 2016-06-16 2017-12-21 Oncoselect Therapeutics, Llc Porphyrin compounds and compositions useful for treating cancer
CA3082036A1 (en) 2017-12-29 2019-07-04 Ap Biosciences, Inc. Monospecific and bispecific proteins with immune checkpoint regulation for cancer therapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4867973A (en) * 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
US4732863A (en) * 1984-12-31 1988-03-22 University Of New Mexico PEG-modified antibody with reduced affinity for cell surface Fc receptors
US4698420A (en) * 1985-02-25 1987-10-06 Xoma Corporation Antibody hybrid molecules and process for their preparation
DE3617430A1 (de) * 1986-05-23 1987-11-26 Merck Patent Gmbh Perlglanzpigmente
ATE106249T1 (de) * 1987-11-05 1994-06-15 Hybritech Inc Polysaccharidmodifizierte immunglobuline mit reduziertem immunogenem potential oder verbesserter pharmakokinetik.
DE3873887T2 (de) * 1987-12-02 1993-02-04 Neorx Corp Spaltbare immun-conjugate fuer die abgabe und freisetzung von agenzien in natuerlicher form.
US5061641A (en) * 1988-04-01 1991-10-29 Immunomedics, Inc. Method for radiolabeling proteins
US5541297A (en) * 1988-04-01 1996-07-30 Immunomedics, Inc. Therapeutic conjugates of toxins and drugs

Also Published As

Publication number Publication date
ES2208639T3 (es) 2004-06-16
EP0651646A1 (de) 1995-05-10
EP1283059A2 (de) 2003-02-12
DE69333182T2 (de) 2004-07-15
EP0651646B1 (de) 2003-09-03
JP2942356B2 (ja) 1999-08-30
EP1283059A3 (de) 2004-01-02
DK0651646T3 (da) 2003-10-13
JPH08500084A (ja) 1996-01-09
US5541297A (en) 1996-07-30
ATE248858T1 (de) 2003-09-15
CA2118032C (en) 1998-09-29
WO1993023062A1 (en) 1993-11-25
CA2118032A1 (en) 1993-11-25
EP0651646A4 (de) 1997-07-09
US5601825A (en) 1997-02-11
PT651646E (pt) 2003-12-31

Similar Documents

Publication Publication Date Title
DE69333182D1 (de) Therapeutische konjugate von toxinen und medikamenten
PT740650E (pt) Co-farmacos como um metodo de administracao controlada de farmacos
DE60234782D1 (de) Behandlungsverfahren mit liganden-immunogenkonjugaten
HUP0300421A2 (hu) Kezelési eljárás ligand-immunogén konjugátumok felhasználásával
FI884013A0 (fi) Konjugat av cytokiner med immunoglobuliner.
DE69010206D1 (de) Stabilisierte protein- oder peptidkonjugate.
DK651088D0 (da) Konjugater af laegemidler og monoklonale antistoffer
BR0312297A (pt) Conjugados veìculos de hapteno e seu uso
BR9915852A (pt) Conjugado de hapteno-portador para tratamento e prevenção do vìcio da nicotina
NO20015584L (no) Langtidsvarende insulintropiske peptider og konjugater samt anvendelse for fremstilling av medikamenter for behandling
PT1323346E (pt) Administracao transepitelial de antigenicos com a finalidade de provocar tolerancia e imunidade
TR200101751T2 (tr) Poliol-IFN-beta konjugatları
SE9703191D0 (sv) Medicament for improvement of duration of muscle function or treatment of muscle disorders or diseases
ATE219363T1 (de) Lösliche prodrugs von paclitaxel
DE69925830D1 (de) Peg-lhrh analog konjugate
BR0112591A (pt) Derivados de acridina e sua aplicação como medicamento
ES2173641T3 (es) Composicion de derivados opiaceos para la fabricacion de medicamentos.
BR9909011A (pt) Análogo de antìgeno covalentemente reativo (craa), processos para tratar um estado de doença em um paciente inibindo-se irreversivelmente a ação de um anticorpo catalìtico, e para estimular a produção de anticorpos com atividade catalìtica, anticorpo catalìtico, processos para tratar um estado de doença em um paciente, para inibir o anticorpo catalìtico, e para imunizar passivamente um paciente, e, preparação farmacêutica para tratar uma condição patológica relacionada com a presença de anticorpos catalìticos endogenamente produzidos
KR102015524B1 (ko) 압타머-약물 콘쥬게이트 및 그 용도
PT814843E (pt) Conjugados de hapteno-transportador para utilizacao na terapia de abuso de drogas
DK522186A (da) Melatoninmaterialer og deres anvendelser
DE69019959D1 (de) Ortspezifische in-vivo-aktivierung von therapeutischen arzneimitteln.
ES2059312T3 (es) Medicamento que puede administrarse por via nasal, procedimiento para su preparacion y su aplicacion.
BR0116653A (pt) Medicamento contendo uma poliamina como substância ativa
AU3445489A (en) Luminide and macroluminide class of pharmaceuticals

Legal Events

Date Code Title Description
8364 No opposition during term of opposition